Dr. Berman brings more than 20 years of entrepreneurial and industry experience at the intersection of science and business. He is the founder, former Chief Executive Officer, and current Executive Chairman and Chairman of the Board of Directors of Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company (founded in 2020, IPO in December 2022) developing multi-modality Regulatory T Cell (Treg) therapies for neurodegenerative, autoimmune, and metabolic diseases. He is member of the board of directors of Atea Pharmaceuticals (NASDAQ: AVIR) and an advisor and Board Observer of Mammogen, Inc.
Before founding Coya, Berman served as founder and board member of Imaware Inc., a private company focused on at-home health testing and diagnostics for consumers, employers, and health systems, from 2018 until its acquisition in 2024. Earlier in his career, Berman held leadership roles at AbbVie, Eli Lilly, and Novartis, where he contributed to the launches of Venclexta (venetoclax) for chronic lymphocytic leukemia, Alimta (pemetrexed) for non–small cell lung cancer, and Focalin XR (dexmethylphenidate hydrochloride) for ADHD. Berman earned his B.A. in Biology from the University of Michigan and his M.S. and Ph.D. in Neuroscience and Pharmacology from Weill Cornell Medical College.
Back to Team